Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $6.25, for a total transaction of $104,168.75. Following the completion of the sale, the insider owned 1,226,507 shares in the company, valued at approximately $7,665,668.75. This trade represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Beth Hecht also recently made the following trade(s):

• On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The stock was sold at an average price of $7.45, for a total transaction of $124,169.15.
• On Friday, January 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.43, for a total transaction of $123,835.81.

Xeris Biopharma Stock Up 2.2%

Xeris Biopharma stock traded up $0.13 during mid-day trading on Wednesday, hitting $6.07. The company’s stock had a trading volume of 2,355,176 shares, compared to its average volume of 2,095,509. The stock has a market capitalization of $1.01 billion, a P/E ratio of -606.39 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a twelve month low of $3.65 and a twelve month high of $10.08. The stock’s fifty day moving average price is $7.18 and its two-hundred day moving average price is $7.62.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $85.81 million during the quarter, compared to the consensus estimate of $86.00 million. Xeris Biopharma had a negative return on equity of 3.01% and a net margin of 0.19%. Equities analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in XERS. Kestra Advisory Services LLC acquired a new position in Xeris Biopharma in the fourth quarter valued at about $25,000. AlphaQuest LLC bought a new stake in shares of Xeris Biopharma in the 3rd quarter valued at about $35,000. Caitong International Asset Management Co. Ltd raised its position in shares of Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Xeris Biopharma by 29.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after purchasing an additional 1,820 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma News Roundup

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 results beat on EPS and management set aggressive revenue goals — Xeris reported Q4 EPS of about $0.06 (vs. ~$0.03 consensus) and highlighted record revenue growth plus a target of over 30% revenue growth for 2026 while increasing investment in Recorlev and advancing XP‑8121, which supports the recent upside in the stock. Xeris targets over 30% revenue growth in 2026 while expanding Recorlev investment and advancing XP-8121
• Positive Sentiment: Analyst support: HC Wainwright maintains a Buy and $10 price target and published multi‑year EPS runway (FY2026–FY2030 forecasts showing progressive profit improvement), which reinforces investor confidence in upside to the current share price. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright
• Positive Sentiment: Bull case commentary: A recent Seeking Alpha piece argues Xeris is undervalued given its drug portfolio and development pipeline, which can attract value‑oriented and biotech growth investors. Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio
• Neutral Sentiment: Earnings call and transcripts are available for detail — investors can review management’s commentary on margin progress, Recorlev commercialization plans and pipeline timing in the Q4 2025 call transcript. Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
• Neutral Sentiment: Market reaction coverage: Several outlets note the stock rallied following the quarter and guidance, reflecting short‑term trader interest on the beat and outlook. Xeris Biopharma stock up nearly 3% after Q4 EPS beat, above estimate guidance
• Negative Sentiment: Recorlev patent disputes pose downside risk — coverage highlights active patent battles around Recorlev that could create legal uncertainty, potential injunction or royalty impacts that would weigh on valuation if outcomes are adverse. Xeris Biopharma Balances New Profitability With Recorlev Patent Battles
• Negative Sentiment: Analyst estimate trims for near‑to‑midterm years — HC Wainwright’s note included small reductions to FY2026–FY2029 EPS forecasts (while keeping a Buy), signaling expected slower near‑term margin progression and tempering upside in the near term. Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright

Analysts Set New Price Targets

Several research firms recently weighed in on XERS. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Piper Sandler lifted their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Finally, Barclays started coverage on Xeris Biopharma in a report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.08.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.